2023-505839-12-01RecruitingPhase 3
the BIRDIE trial
BIomarker-dRiven Dosing Interval Extension of biologics in asthma (the BIRDIE trial)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Dec 2025
Brief summary (registry, in English)
1. To evaluate if it is possible to extend the dosing interval of mepolizumab, driven by eosinophil levels as biomarker in patients with severe eosinophilic asthma without loss of asthma control 2. To evaluate if it is possible to extend the dosing interval of dupilumab, driven by FeNO as biomarker in patients with severe T2-high asthma without loss of asthma control
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 23 Jun 2023
- Start date
- 26 Feb 2024
- Lead sponsor
- Sint Franciscus Vlietland Groep Stichting
- Diseases
- Asthma
- EU CT number
- 2023-505839-12-01
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 80
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with maintenance OCS, defined as treatment with OCS during 14 or more subsequent days, in the last 6 months
- Treatment with immunosuppressants (other than mepolizumab, dupilumab or corticosteroids) in the last 6 months
- Treatment with, or switching between, other biologics than the drug of interest in the 6 months before inclusion.
Other illness
- Pulmonary disease(s) other than asthma (including EGPA)
Other
- Pregnancy
Who the study is looking for
- Severe asthma as primary indication for treatment with mepolizumab (one dose every 4 weeks) or dupilumab (one dose every 2 weeks) for the last 6 months.
- Stable asthma (an ACQ <1.5 and no severe asthma exacerbations) for at least 6 months.
- Sufficient understanding of the Dutch language
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sint Franciscus Vlietland Groep Stichting | Rotterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.